Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Sinovac Biotech Ltd (SVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: SVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 642.44M USD | Price to earnings Ratio 6.66 | 1Y Target Price 3.52 |
Price to earnings Ratio 6.66 | 1Y Target Price 3.52 | ||
Volume (30-day avg) - | Beta 0.06 | 52 Weeks Range 6.47 - 6.47 | Updated Date 06/29/2025 |
52 Weeks Range 6.47 - 6.47 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 850.08% | Basic EPS (TTM) 0.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.61% | Operating Margin (TTM) 42.26% |
Management Effectiveness
Return on Assets (TTM) 11.46% | Return on Equity (TTM) 25.16% |
Valuation
Trailing PE 6.66 | Forward PE - | Enterprise Value 297087285 | Price to Sales(TTM) 1.83 |
Enterprise Value 297087285 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.04 | Shares Outstanding 99294704 | Shares Floating 59508332 |
Shares Outstanding 99294704 | Shares Floating 59508332 | ||
Percent Insiders 51.42 | Percent Institutions 32.02 |
Upturn AI SWOT
Sinovac Biotech Ltd
Company Overview
History and Background
Sinovac Biotech Ltd. was founded in 1999. It is a Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines for the prevention of infectious diseases. A significant milestone was its role in developing CoronaVac, a COVID-19 vaccine. The company has evolved from a domestic Chinese vaccine provider to a global player, particularly due to its COVID-19 vaccine production and distribution.
Core Business Areas
- Vaccine Development and Manufacturing: Sinovac's primary business is the development and manufacturing of vaccines. This includes R&D, clinical trials, large-scale production, and commercialization of its vaccine portfolio.
- Infectious Disease Prevention: The company focuses on preventing a range of infectious diseases, with a particular emphasis on viral diseases that pose significant public health threats.
Leadership and Structure
Sinovac Biotech Ltd. is led by its executive management team, including its Chairman and CEO. The organizational structure is typical of a biopharmaceutical company, with departments dedicated to research and development, manufacturing, quality control, sales and marketing, and corporate functions.
Top Products and Market Share
Key Offerings
- Product Name 1: CoronaVac (COVID-19 Vaccine) - Description: An inactivated vaccine against COVID-19. It has been widely used globally, particularly in developing countries. Market Share: While exact current market share is fluid and geographically diverse, it held a significant portion of the global COVID-19 vaccine market, especially in 2021 and 2022. Number of Users: Billions of doses administered globally. Competitors: Pfizer-BioNTech (Comirnaty), Moderna (Spikevax), AstraZeneca (Vaxzevria), Johnson & Johnson (Janssen), Sputnik V.
- Product Name 2: Influenza Vaccines - Description: Sinovac develops and manufactures seasonal influenza vaccines for the Chinese market. Competitors: Sanofi Pasteur, GlaxoSmithKline (GSK), CSL Limited.
- Product Name 3: Enterovirus 71 (EV71) Vaccine - Description: A vaccine to prevent hand, foot, and mouth disease caused by EV71. Competitors: Primarily domestic Chinese manufacturers.
Market Dynamics
Industry Overview
The global biopharmaceutical and vaccine industry is characterized by high R&D costs, stringent regulatory requirements, and significant market potential driven by public health needs and emerging infectious diseases. The COVID-19 pandemic significantly boosted the vaccine market, accelerating innovation and production capabilities.
Positioning
Sinovac is a prominent player in the Chinese biopharmaceutical market and has gained global recognition due to its COVID-19 vaccine. Its strengths lie in its manufacturing capacity and established distribution channels within China. Its competitive advantages include its experience in vaccine development and its ability to produce large volumes of affordable vaccines.
Total Addressable Market (TAM)
The TAM for vaccines is vast and growing, encompassing preventative healthcare for infectious diseases worldwide. This includes routine immunizations, pandemic preparedness, and new vaccine development. Sinovac is positioned to capture a significant portion of this TAM, particularly in emerging markets where affordability and accessibility are key factors.
Upturn SWOT Analysis
Strengths
- Established manufacturing capacity for vaccines.
- Significant experience in vaccine research and development.
- Strong presence and distribution network in the Chinese market.
- Global recognition and supply chain established through COVID-19 vaccine.
Weaknesses
- Reliance on a few key products, especially historically.
- Potential for future funding challenges if R&D pipeline is not robust.
- Geopolitical and regulatory risks associated with international operations.
Opportunities
- Development of new vaccines for emerging infectious diseases.
- Expansion into new international markets.
- Partnerships and collaborations for R&D and commercialization.
- Leveraging existing manufacturing infrastructure for other biologics.
Threats
- Increasing competition in the vaccine market.
- Stringent regulatory approvals and compliance.
- Public perception and vaccine hesitancy.
- Patent expirations and generic competition for older products.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Moderna, Inc. (MRNA)
- AstraZeneca PLC (AZN)
- Sanofi S.A. (SNY)
- GlaxoSmithKline plc (GSK)
Competitive Landscape
Sinovac faces intense competition from established global pharmaceutical giants and other vaccine manufacturers. Its advantage lies in its ability to produce cost-effective vaccines and its strong position in the Chinese market. However, competitors like Pfizer and Moderna have shown strong innovation and market penetration with mRNA technology, posing a significant challenge.
Growth Trajectory and Initiatives
Historical Growth: Sinovac's historical growth was steady but significant in the Chinese domestic market. The advent of the COVID-19 pandemic provided an unprecedented surge in growth due to the global demand for CoronaVac. Post-pandemic, the growth trajectory is expected to normalize and depend on its pipeline.
Future Projections: Future projections for Sinovac will largely depend on the success of its R&D pipeline, including new vaccine candidates for other diseases, and its ability to maintain market share in its existing segments. Analyst estimates would provide more granular insights.
Recent Initiatives: Recent initiatives likely involve expanding its R&D pipeline, exploring new therapeutic areas, strengthening international partnerships, and potentially exploring acquisitions to diversify its product portfolio and revenue streams.
Summary
Sinovac Biotech Ltd. has demonstrated significant growth, particularly driven by its COVID-19 vaccine, establishing a strong manufacturing base and global presence. While it holds a considerable position in China and emerging markets, it faces stiff competition from global leaders in vaccine development. Sustaining growth will hinge on diversifying its product pipeline and ongoing innovation to address future public health needs.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company financial reports (e.g., SEC filings)
- Industry analysis reports
- Financial news and data providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Publicly available company information
Disclaimers:
This JSON output is generated based on publicly available information and general industry knowledge. It is not exhaustive and may not reflect the most up-to-date financial or market data. Investment decisions should be based on thorough personal research and consultation with a qualified financial advisor. Market share data is illustrative and may vary based on specific reporting periods and methodologies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sinovac Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-11-03 | Chairman, CEO, Pres, MD, GM & Sec. Dr. Weidong Yin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1959 | Website http://www.sinovacbio.com |
Full time employees 1959 | Website http://www.sinovacbio.com | ||
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.